Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
SF Express: From Delivery to E-Commerce
Zhu, Feng; Lane, DavidCaso HBS-616003-EServicios y operacionesShunfeng Express (SF), China's leading express delivery firm, in May 2014 opened the first 500 of several thousand Heike stores, which allowed consumers to buy and try out SF's own e-commerce offerings, in addition to other services. As an example of China's "online-to-offline" trend in e-commerce, Heike stores allowed SF to leverage its logistics and IT expertise to differentiate itself from its rivals in express delivery. As yet unclear was whe...Desde 8,20 €
-
Social Business at Novartis: Arogya Parivar
Porter, Michael E.; Kramer, Mark R.; Lane, DavidCaso HBS-715411-EDirección estratégicaLate in 2013, Novartis CEO Joseph Jimenez was considering how and whether to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India, while expanding access to medicine and health information to millions of Indian villagers.Desde 8,20 €
-
Supply Chain Finance at Procter & Gamble
Esty, Benjamin C.; Mayfield, E. Scott; Lane, DavidCaso HBS-216039-EFinanzasIn April 2013, Procter & Gamble (P&G), the world's largest consumer packaged goods (CPG) company, announced that it would extend its payment terms to suppliers by 30 days. At the same time, P&G announced a new supply chain financing (SCF) program giving sDesde 8,20 €
-
L'Occitane en Provence
Becker, Bo; Beyersdorfer, Daniela; Mayfield, E. Scott; Yamazaki, MayukaCaso HBS-212051-EFinanzasCosmetics company L'Occitane en Provence must decide if it is the right time to go public, and, if so, where to list. The firm could list on Euronext in Paris, close to the firm's headquarters in southern France, on one of the large exchanges in the United States, or perhaps in Asia, where much of the firm's future growth is expected. The case provides opportunities to discuss the benefits and costs of going public, including valuation implicatio...Desde 8,20 €
-
Endeavor: Miami Heats Up
Sahlman, William A.; Nanda, Ramana; Lane, David; Mazzanti, LisaCaso HBS-814043-EEndeavor Global was a nonprofit that for 15 years had worked to nurture entrepreneurship in emerging markets by selecting local high-impact entrepreneurs for mentoring and aid in scaling up their businesses from committed local business leaders. In summer 2012, Endeavor received an invitation to replicate its model in Miami, Florida, and the Endeavor board was meeting to debate the value of such a move. At issue were questions of organizational m...Desde 8,20 €
-
Amazon Buys Whole Foods
Alvarez, Jose B.; Lane, David; Coughlin, JoniCaso HBS-518056-EServicios y operacionesThe June 2017 news that e-commerce giant Amazon was paying $13.7 billion for organic supermarket chain Whole Foods precipitated a broad sell-off in the shares of grocery retailers and suppliers. Behind the precipitous declines lay recognition that Amazon's bold move into brick and mortar assets offered transformational opportunities. Amazon could gain expertise in perishable product sales and procurement, plus access to 30 million well-off shoppe...Desde 8,20 €
-
ReSource Pro, Teaching Note
Kerr, William R.; Lane, DavidNota del Instructor HBS-813137-EIniciativa emprendedoraTeaching Note for 812031Desde 0,00 €
-
Cyberdyne: A Leap to the Future, Teaching Note
Chung, Doug J.; Yamazaki, MayukaNota del Instructor HBS-516114-EMarketingTeaching note for case 516072.Desde 0,00 €
-
Sonoco Products Company (A), (B), and (C), and Sonoco Products Company (A) (Abridged), Teaching Note
Groysberg, Boris; Lane, David; Thomas, David A.Nota del Instructor HBS-407058-ELiderazgo y Dirección de personasTeaching Note to 405-009, 405-010, 407-063 and 410082.Desde 0,00 €
-
MedImmune Ventures
Hamermesh, Richard G.; Lane, DavidCaso HBS-814023-EIniciativa emprendedoraRon Laufer is the new Senior Managing Director of MedImmune Ventures', the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.Desde 8,20 €